Generic Name:
ranolazine
Project Status:
Active
Therapeutic Area:
Stable angina pectoris, adults
Manufacturer:
KYE Pharmaceuticals Inc.
Brand Name:
Corzyna
Project Line:
Reimbursement Review
Project Number:
SR0655-000
Details
Manufacturer Requested Reimbursement Criteria1:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.